



Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 6, 2024-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will be held virtually on February 13-14, 2024.

Dr. Brady's conversation with Justin Kim, Senior Research Analyst at Oppenheimer & Co., is scheduled to begin at 4:00 p.m. ET Tuesday, February 13, 2024. To listen to the live webcast, log in to the Investors & Media section of the Aldeyra website at <https://ir.aldeyra.com>. Following the fireside chat, the webcast will be archived for 90 days.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240206438268/en/): <https://www.businesswire.com/news/home/20240206438268/en/>

Investor & Media:

David Burke

Tel: (917) 618-2651

investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.